Volume 12, Issue 2 (Summer 2015)                   bloodj 2015, 12(2): 163-172 | Back to browse issues page

XML Persian Abstract Print

Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
Zadsar M, Naserani Pour M, Chegini A, Lotfi A, Mojtabavi Naeeni M. Platelet consumption, indications, transfusion triggers, and response to treatment in hospital wards in Tehran . bloodj 2015; 12 (2) :163-172
URL: http://bloodjournal.ir/article-1-885-en.html
Platelet consumption, indications, transfusion triggers, and response to treatment in hospital wards in Tehran
M. Zadsar * , M. Naserani Pour , A. Chegini , A.H. Lotfi , M. Mojtabavi Naeeni
Keywords: Key words : Blood Platelets, Platelet Transfusion, Platelet Count, Transfusion Medicine
Full-Text [PDF 274 kb]   (6212 Downloads)     |   Abstract (HTML)  (7499 Views)
Full-Text:   (91091 Views)
References :  
  1. Aursnes I. Blood platelet production and red cell leakage to lymph during thrombocytopenia. Scand J Haematol 1974; 13(3): 184-95.
  2. Slichter SJ. Background, rationale, and design of a clinical trial to assess the effects of platelet dose on bleeding risk in thrombocytopenic patients. J Clin Apher 2006, 21(1): 78-84.
  3. Arnold DM, Crowther MA, Cook RJ, Sigouin C, Heddle NM, Molnar L, Cook DJ. Utilization of platelet transfusions in the intensive care unit: indications, transfusion triggers, and platelet count responses. Transfusion 2006; 46(8): 1286-91.
  4. Marwaha N, Sharma RR. Consensus and controversies in platelet transfusion. Transfus Apher Sci 2009; 41(2): 127-33.
  5. Heal JM, Blumberg N. Optimizing platelet transfusion therapy. Blood Rev 2004; 18(3): 149-65.
  6. Davey M. Trends in platelet utilization in Canada 1981–1987. Curr Stud Hematol Blood Transf 1998; 54: 89-93.
  7. Greeno E, McCullough J, Weisdorf D. Platelet utilization and the transfusion trigger: a prospective analysis. Transfusion 2007; 47(2): 201-5.
  8. Schlossberg HR, Herman JH. Platelet dosing. Transfus Apher Sci 2003; 28(3): 221-6.
  9. Cameron B, Rock G, Olberg B, Neurath D. Evaluation of platelet transfusion triggers in a tertiary care hospital. Transfusion 2007; 47(2): 206-11.
  10. Tinmouth AT, Fredman J. Prophylactic platelet transfusions: which dose is the best dose? A review of the literature. Transfus Med Rev 2003; 17(3): 181-93.
  11. Heckman KD, Weiner GJ, Davis CS, Strauss RG, Jones MP, Burns CP. Randomized study of prophylactic platelet transfusion threshold during induction therapy for adult acute leukemia: 10,000/microL versus 20,000/microL. J Clin Oncol 1997; 15(3):  1143-9.
  12. Slichter SJ, Davis K, Enright H, Braine H, Gernsheimer T, Kao KJ, et al. Factors affecting posttransfusion platelet increments, platelet refractoriness, and platelet transfusion intervals in thrombocytopenic patients. Blood 2005; 105(10): 4106-14.
  13. Rebulla P, Finazzi G, Marangoni F, Avvisati G, Gugliotta L, Tognoni G, et al. The threshold for platelet transfusions in adults with acute myeloid leukemia. Gruppo Italiano Malattie Ematologiche Maligne dell'Adulto. N Engl J Med 1997; 337(26): 1870-5.
  14. Bishop JF, Matthews JP, Yuen K, McGrath K, Wolf MM, Szer J. The definition of refractoriness to platelet transfusion. Transfusion Med 1992; 2(1): 35-41.
  15. Rao MP, Bora Lessa H, Morgan C, Soni N, Goldhill DR, Brett SJ, et al. Blood component use in critically ill patients. Anaesthesia 2002; 57(6): 530-4.
  16. Diedrich B, Remberger M, Shanwell A, Svahn BM, Ringdén O. A prospective randomized trial of prophylactic platelet transfusion trigger of 10 x 10(9) per L versus 30 x 10(9) per L in allogeneic hematopoietic progenitor transplant recipients. Transfusion 2005; 45(7): 1064-72.
 
  1. Friedmann AM, Sengul H, Lehmann H, Schwartz C, Goodman S. Do basic laboratory tests or clinical observations predict bleeding in thrombocytopenic oncology patients? A reevaluation of prophylactic platelet transfusions. Transfus Med Rev 2002; 16(1): 34-45
  2. Bishop JF, Matthews JP, McGrath K, Yuen K, Wolf MM, Szer J. Factors influencing 20-h increments after platelet transfusion. Transfusion 1991; 31(5): 392-6.
  3. Schiffer CA, Anderson KC, Bennett CL, Bernstein S, Elting LS, Goldsmith M, et al. Platelet transfusion for patients with cancer: Clinical practice guidelines of the American Society of Clinical Oncology. J Clin Oncol 2001; 19: 1519-38.
  4. British Committee for Standards in Haematology, Blood Transfusion Task Force. Guidelines for the use of platelet transfusions. Br J Haematol 2003; 122(1): 10-23.
  5. Collinns G, Murphy MF, Stanworth SJ. Current controversies about the indications for platelet transfusion with a focus on patients with hematological malignancies. Transfusion Alternatives in Transfusion Medicine 2006; 2: 86-94.
  6. Cameron B, Rock G, Olberg B, Neurath D. Evaluation of platelet transfusion triggers in a tertiary care hospital. Transfusion 2007; 47(2): 206-11.
  7. Rebulla P. A mini-review on platelet refractoriness. Haematologica 2005; 90(2): 247-53.
  8. Spiess BD, Royston D, Levy JH, Fitch J, Dietrich W, Body S, et al. Platelet transfusions during coronary artery bypass graft surgery are associated with serious adverse outcomes. Transfusion 2004; 44(8): 1143-8.
  9. Cook D, Crowther M, Meade M, Rabbat C, Griffith L, Schiff D, et al. Deep venous thrombosis in medical, surgical critically ill patients: prevalence, incidence and risk factors. Crit Care Med 2005; 33(7): 1565-71.
  10. Heim D, Passweg J, Gregor M, Buser A, Theocharides A, Arber C, et al. Patient and product factors affecting platelet transfusion results. Transfusion 2008; 48(4): 681-7.
  11. Refaai MA, Phipps RP, Spinelli SL, Blumberg N. Platelet transfusion: impact on hemostasis, thrombosis, inflammation and clinical outcomes. Thromb Res 2011; 127(4): 287-91.
  12. Contreras M. ABC of transfusion. 4th ed. Philadelphia: Wiley Blackwell; 2010. p. 22-6.
  13. Slichter SJ. Platelet transfusions a constantly are evolving therapy. Thromb Haemost 1991; 66(1): 178-88.
  14. Panzer S, Maier F, Höcker P, Mayr WR, Hinterberger W. Thrombocyte transfusion: increase in platelets in relation to clinical and immunologic prerequisites. Infusionsther Klin Ernahr 1987; 14 Suppl 2: 10-4. [Article in German]
  15. Rinder HM, Arbini AA, Snyder EL. Optimal dosing and triggers for prophylactic use of platelet transfusions. Curr Opin Hematol 1999; 6(6): 437-41.
  16. Practice guidelines for blood component therapy: A report by the American Society of Anesthesiologist Anesthesiology Task Force on Blood Component Therapy. Anesthesiology 1996; 84(3): 732-47.
  17. Stéphan F, Hollande J, Richard O, Cheffi A, Maier-Redelsperger M, Flahault A. Thrombocytopenia in a surgical ICU. Chest 1999; 115(5): 1363-70.
 
  1. Hod E, Schwartz J. Platelet transfusion refractoriness. Br J Haematol 2008; 142(3): 348-60.
 
 
 
 


 
 
 
 
Sci J Iran Blood Transfus Organ 2015; 12(2): 163-172
 
Original  Article
 

 

Platelet consumption, indications, transfusion triggers,
and response to treatment in hospital wards
in Tehran
 
Zadsar M.1, Naserani Pour M.1,2, Chegini A.1,2, Lotfi A.H.3, Mojtabavi Naeeni M.1,2
 
 
1Blood Transfusion Research Center, High Institute for Research and Education in Transfusion Medicine, Tehran, Iran
2Tehran Regional Educational Blood Transfusion Center, Tehran, Iran
3Laleh Hospital, Tehran, Iran
 
Abstract
Background and Objectives
Thrombocytopenia is one of the most prevalent complications in ICU admitted patients that could increase the risk of hemorrhage, duration of ICU inhabitant, morbidity and mortality. Platelet transfusion is used to prevent or treat hemorrhagic conditions. Indications, triggers and response to platelet transfusion in ICU of two hospitals in Tehran were studied.
 
Materials and Methods
In the descriptive study, 380 thrombocytopenic ICU admitted adult patients were enrolled. Indications, triggers, response to platelet transfusion (CCI), type of component, prophylactic or therapeutic transfusion and number of transfused units were studied.
 
Results
Among 380 patients, 124 (32.2%) received platelet transfusion, 64 (51.6%) were prophylactic and the rest were therapeutic; 30 (24.2%) used the aphaeresis platelet and the rest were administered RDP homologous PC. The mean rate of transfused units was found as 4.5 and in 58 (46.8%) of cases the non-immunologic causes of refractoriness were found. Triggers of prophylactic platelet transfusion (33 ± 4 × 109/L) and therapeutic platelet transfusion (58 ± 8 × 109/L) showed significant differences (p value = 0.04). Triggers of transfusion aphaeresis (19 × 109/L) compared to RDP homologous PC (55 × 109/L) were also shown to be significantly different (p = 0.01).  The mean rates of 1st hour and 20th hour CCIs were 3700 ± 1850 and 3300 ± 1840, respectively.
 
Conclusions
Almost half of transfusions in ICU were prophylactic. More than half of ICU patients who received platelet transfusion were unable to build a successful increment after a single transfusion.
 
Key words: Blood Platelets, Platelet Transfusion, Platelet Count, Transfusion Medicine
 
 
 
Received:    6 Aug 2014
Accepted:  18 Apr 2015
 
 
 
 

Correspondence: Zadsar M., MD. Specialist in Infectious Diseases and Tropical Medicine. Assistant Professor of Blood Transfusion Research Center, High Institute for Research and Education in Transfusion Medicine.
P.O.Box: 14665-1157, Tehran, Iran. Tel: (+9821) 8898997; Fax: (+9821) 88963034
E-mail: maryam_zad@yahoo.com
Type of Study: Research | Subject: Blood Transfusion
Add your comments about this article : Your username or Email:
CAPTCHA
Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

© 2025 CC BY-NC 4.0 | Journal of Iranian Blood Transfusion

Designed & Developed by: Yektaweb